Robert Brooks
Cambridge, MA (USA)
Role(s):
C-Level Executive (CEO, CFO, etc.)
Aurora BioPharma, Inc.
Find More Startups
Startup
Location:
Cambridge
Industry:
Other
Year Founded:
2015
Number Employees:
1-10 people
Business Stage:
Growth (profitable)
Entity Type:
"C" Corporation
Description:
Aurora BioPharma is a clinical stage biotechnology company developing genetically reprogrammed T Cell therapy to treat Solid and Liquid tumors.
This 21st century therapy combines immunotherapy with gene reprogramming to produce a “living drug” of immune T Cells serial killers that target and kill cancer cells. Originally developed in Israel, the treatment begins with blood taken from a patient, T-cells extracted, genetically engineered to produce special receptors on their surface called chimeric antigen receptors (CARs). CARs are proteins that allow the T cells to recognize a specific protein (antigen) on tumor cells. In Leukemia, CAR T Cell therapy has shown a medical breakthrough of over 60% remissions in patients.
Aurora has one of the most advanced clinical pipeline's using CAR T Cell Therapy in solid tumors, with Phase I/IIa clinical trials completed in two orphan indications, Sarcoma (Osteosarcoma) and Glioblastoma. Osteosarcoma is the most common bone cancer, no new treatment has been approved in 20 years. Aurora’s CAR T agent AU-101 completed a Phase I/IIa trial in 19 Sarcoma (16 Osteosarcoma) patients, meeting its safety endpoint, with strong signs of tumor killing, and 3 long term survivors. Glioblastoma is the most common and lethal form of brain cancer, with survival under 15 months with current standard of care. Aurora’s CAR T bispecific AU105 showed in a completed Phase I/IIa of 16 newly diagnosed GBM patients that it met its endpoint of safety, with strong signs of tumor killing efficacy, and Overall Survival double the median historic OS with Standard of Care.